# Optimal Neo-adjuvant Combination Scheme of Ipilimumab and Nivolumab

> **NCT02977052** · PHASE2 · UNKNOWN · sponsor: **The Netherlands Cancer Institute** · enrollment: 186 (actual)

## Conditions studied

- Malignant Melanoma Stage III

## Interventions

- **DRUG:** Ipilimumab
- **DRUG:** Nivolumab
- **PROCEDURE:** Surgery
- **PROCEDURE:** Blood for PBMCs
- **PROCEDURE:** Biopsies

## Key facts

- **NCT ID:** NCT02977052
- **Lead sponsor:** The Netherlands Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-11-24
- **Primary completion:** 2020-01-03
- **Final completion:** 2025-06
- **Target enrollment:** 186 (ACTUAL)
- **Last updated:** 2023-11-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02977052

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02977052, "Optimal Neo-adjuvant Combination Scheme of Ipilimumab and Nivolumab". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02977052. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*